Simcere Of China, OSI Of U.S. Sign Development Deal For Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
China's Simcere has signed an agreement with U.S.-based OSI Pharmaceuticals to take from development to marketing OSI's OSI-930 KDR/Kit inhibitor for treating various cancers